Prestige Consumer Healthcare trims fiscal 2027 outlook on Clear Eyes supply issue

Prestige Consumer Healthcare Inc. (NYSE: PBH) reported second quarter fiscal 2027 results on November 5, 2026, for the period ended September 30, 2026, and lowered its full-year guidance. CEO Ron Lombardi said the company is updating its fiscal 2027 outlook for revenues to $1,280 million to $1,290 million and adjusted diluted EPS of $4.48 to $4.55, primarily to reflect recent variability in Clear Eyes production at Pillar5, which is expected to reduce product availability and revenue in the second half¹. The prior outlook had called for revenue of $1,290 to $1,315 million and adjusted diluted EPS of $4.55 to $4.65¹. Adjusted free cash flow guidance was also reduced, to $265 million or more from $270 million or more previously¹.

Lombardi added that while supply remains limited for Clear Eyes, the company continues to invest in its Pillar5 production site with the intent of delivering consistent quality output for the brand's long-term growth¹. He said the rest of the portfolio outlook is unchanged, with the base business delivering growth and recent acquisitions on track to meet prior guidance¹.

For the quarter, reported revenue was $336.3 million, up 22.7% from $274.1 million a year earlier, but down 1.6% excluding currency effects and a $65.1 million contribution from the Breathe Right portfolio and LaCorium acquisitions¹. Those deals closed in June and July, respectively¹. Reported net income was $25.3 million, or $0.53 per diluted share, compared to $42.2 million, or $0.86 per diluted share, a year earlier¹.

On the balance sheet, net debt stood at approximately $2 billion as of September 30, 2026, after the company issued $400 million of new 6.25% senior notes due July 2034 on July 15, 2026, replacing notes previously due in fiscal 2028¹.